News

SORT BY YEAR
28 October, 2020

Ally Bridge Portfolio News – miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.

Acquisition includes clinical stage anti-IGF–1R monoclonal antibody, VRDN-001, intended for the treatment of thyroid eye disease (TED). Company plans to use private placement financing proceeds of $91 million to advance multiple compounds through phase 2 proof of concept studies in TED and to expand its orphan disease pipeline BOULDER, Colo. and WALTHAM, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) —  miRagen Therapeutics, Inc. (“miRagen”) (NASDAQ: MGEN) today announced it has completed the […]

Read More
28 October, 2020

Ally Bridge Portfolio News – Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19

Roche Obtains Exclusive Right to Develop and Distribute AT-527 Outside the United States BOSTON, Mass., October 22, 2020 – Atea Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announces that the company has entered into an […]

Read More
28 October, 2020

Ally Bridge Portfolio News – Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development

NEW YORK – – October 21, 2020 – Nuvation Bio, Inc., a biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology, and Panacea Acquisition Corp. (NYSE: PANA), a special purpose acquisition company (SPAC) sponsored by EcoR1 Capital, today announced they have entered into a definitive […]

Read More
2 October, 2020

Ally Bridge Portfolio News – Pulmonx shares soar 118% in trading debut

(MarketWatch) — Shares of Pulmonx, a maker of treatments for lung diseases including emphysema, rose 118% in their trading debut Thursday, after the company’s initial public offering priced above range. The deal priced at $19 a share, above its proposed price range of $17 to $18. The company upsized the deal on Wednesday and raised […]

Read More
21 September, 2020

Ally Bridge Portfolio News – Illumina to Acquire GRAIL to Launch New Era of Cancer Detection

September 21, 2020 Accelerates Commercialization and Adoption of Transformative Multi-Cancer Screening Test with Potential to Detect More Cancers Earlier and Enable Better Outcomes Adds Multi-Disciplinary Team and Capabilities Harnessing the Power of Next-Generation Sequencing (NGS), Population Scale Clinical Studies, and Machine Learning to Address One of Medicine’s Greatest Challenges Brings Significant New Growth Opportunities in […]

Read More
21 August, 2020

Ally Bridge Portfolio News – Bayer and Hua Medicine announce commercialization agreement

August 17, 2020, Beijing and Shanghai, China Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China Investigational first-in-class glucokinase activator, with a novel mode of action, focused on fixing the glucose sensor and restoring glucose homeostasis for Type 2 diabetes mellitus (“T2DM”) patients, with sustained […]

Read More
21 August, 2020

Ally Bridge Portfolio News – Biotechs Tap Growing U.S. Government Support for Alzheimer’s Research

Federal funding for dementia and Alzheimer’s studies has surged, as venture funding focuses on other diseases Aug 20, 2020 Wall Street Journal Alzheon Inc. will be holding Phase 3 clinical trials of its oral drug ALZ-801 after receiving $47 million from the National Institute on Aging, part of the National Institutes of Health. Biotechnology companies […]

Read More
30 July, 2020

Ally Bridge Portfolio News – Cerevel Therapeutics and Arya Sciences Acquisition Corp II Announce Business Combination, Creating a Publicly Listed Leader in Neuroscience Drug Development

July 30, 2020 07:00 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Cerevel Therapeutics, Inc. (“Cerevel Therapeutics”), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, and Arya Sciences Acquisition Corp II (Nasdaq: ARYBU) (“Arya II”), a special purpose acquisition company or SPAC, sponsored by Perceptive Advisors, today announced they have entered into […]

Read More
7 July, 2020

Ally Bridge Portfolio News – Unum Therapeutics Inc. Announces Acquisition of Kiq LLC

CAMBRIDGE, Mass. and PHILADELPHIA, July 6, 2020 /PRNewswire/ — Unum Therapeutics Inc. (“Unum”) (NASDAQ: UMRX), a biopharmaceutical company focused on developing therapies for solid tumors, today announced it has completed the acquisition of Kiq LLC (“Kiq”), a privately held, biotechnology company focused on the discovery and development of precision kinase inhibitors. Concurrent with the acquisition of Kiq, Unum entered into a […]

Read More
2 July, 2020

Ally Bridge Portfolio News – Goldfinch Bio Secures $100 Million in Series B Financing

Proceeds Support Advancement of Lead Product Candidates GFB-887 and GFB-024 Through Three Clinical Proof-of-Concept Readouts Oversubscribed Round Includes Public Healthcare Funds June 30, 2020 08:00 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the closing […]

Read More